Structural insight into the inhibition of tubulin by vinca domain peptide ligands.
The tubulin vinca domain is the target of widely different microtubule inhibitors that interfere with the binding of vinblastine. Although all these ligands inhibit the hydrolysis of GTP, they affect nucleotide exchange to variable extents. The structures of two vinca domain antimitotic peptides--phomopsin A and soblidotin (a dolastatin 10 analogue)--bound to tubulin in a complex with a stathmin-like domain show that their sites partly overlap with that of vinblastine and extend the definition of the vinca domain. The structural data, together with the biochemical results from the ligands we studied, highlight two main contributors in nucleotide exchange: the flexibility of the tubulin subunits' arrangement at their interfaces and the residues in the carboxy-terminal part of the beta-tubulin H6-H7 loop. The structures also highlight common features of the mechanisms by which vinca domain ligands favour curved tubulin assemblies and destabilize microtubules.
Cormier
Anthony
A
Laboratoire d'Enzymologie et Biochimie Structurales, CNRS, Bat. 34, 1 avenue de la Terrasse, 91198 Gif-sur-Yvette, France.
Marchand
Matthieu
M
Ravelli
Raimond B G
RB
Knossow
Marcel
M
Gigant
Benoît
B
D008024:Ligands; D008870:Microtubules / Q000378:metabolism; D008958:Models, Molecular; D009183:Mycotoxins / Q000378:metabolism; D009842:Oligopeptides / Q000378:metabolism; D017434:Protein Structure, Tertiary; D014404:Tubulin / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D014747:Vinblastine / Q000378:metabolism
D008024:Ligands; D009183:Mycotoxins; D009842:Oligopeptides; D014404:Tubulin; D014747:Vinblastine; C035753:phomopsin; C105791:soblidotin
Proc Natl Acad Sci U S A. 1984 Feb;81(3):771-5
6583675
Methods Mol Med. 2007;137:235-43
18085233
Cancer Sci. 2007 Apr;98(4):598-604
17284247
Biochem Pharmacol. 1993 Apr 6;45(7):1503-15
8471072
Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):122-33
11134934
Nature. 1984 Nov 15-21;312(5991):237-42
6504138
Biochemistry. 1999 Oct 26;38(43):14302-10
10572005
Nature. 2004 Mar 11;428(6979):198-202
15014504
J Biol Chem. 1979 Nov 25;254(22):11696-702
227875
Cell. 2000 Sep 15;102(6):809-16
11030624
J Biol Chem. 1977 May 10;252(9):2891-9
16006
Biochem Pharmacol. 1990 Oct 15;40(8):1859-64
2242019
Biochemistry. 2007 Sep 18;46(37):10595-602
17711308
EMBO J. 1988 Feb;7(2):357-65
3366117
J Biol Chem. 1990 Oct 5;265(28):17141-9
2211617
Biochemistry. 1982 Jun 8;21(12):2996-3006
7104309
J Biol Chem. 2004 Jul 16;279(29):30731-40
15123603
Jpn J Cancer Res. 2000 Jul;91(7):737-47
10920282
Proc Natl Acad Sci U S A. 1987 Aug;84(15):5257-61
3474652
Biochemistry. 2000 Oct 10;39(40):12295-302
11015208
Cell. 1999 Jan 8;96(1):79-88
9989499
J Antibiot (Tokyo). 1998 Apr;51(4):418-22
9630863
Pharmacol Ther. 1992;55(1):31-51
1287674
J Am Chem Soc. 2008 Feb 20;130(7):2351-64
18229928
Nature. 2005 May 26;435(7041):519-22
15917812
Nat Struct Biol. 1998 Jun;5(6):451-8
9628483
Arch Biochem Biophys. 1980 Aug;203(1):404-11
7406508